EP3198033
Notkun á FGFR stökkbrigða genasafni til að bera kennsl á krabbameinssjúklinga sem munu vera móttækilegir fyrir meðhöndlun með FGFR hemli
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
18.9.2015EP published:
16.2.2022EP application number:
15782109.1
EP translation filed:
28.4.2022Grant published:
15.6.2022EPO information:
European Patent Register
Max expiry date:
17.9.2035Expiry date:
17.9.2026Next due date:
30.9.2026
Title in English:
USE OF FGFR MUTANT GENE PANELS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH AN FGFR INHIBITORLanguage of the patent:
English
Timeline
Today
18.9.2015EP application
16.2.2022EP Publication
28.4.2022Translation submitted
15.6.2022Registration published
17.9.2026Expires
Owner
Name:
Janssen Pharmaceutica NVAddress:
Turnhoutseweg 30, 2340 Beerse, BE
Inventor
Name:
KARKERA, JayaprakashAddress:
Spring House Pennsylvania 19477, US
Name:
PLATERO, Suso JesusAddress:
Spring House Pennsylvania 19477, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201462056159 PDate:
26.9.2014Country:
US
Classification
Categories:
C12Q 1/68
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 16.8.2022
Expires: 17.9.2023
Payer: Árnason Faktor ehf.
Number: 9
Paid: 5.9.2023
Expires: 17.9.2024
Payer: Árnason Faktor ehf.
Number: 10
Paid: 7.8.2024
Expires: 17.9.2025
Payer: Árnason Faktor ehf.
Number: 11
Paid: 11.9.2025
Expires: 17.9.2026
Payer: Árnason Faktor ehf.